Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 204

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non‐alcoholic fatty liver disease

Open access
Wang, Weijun, Zhao, Jinfang, Gui, Wenfang, Sun, Dan, Dai, Haijiang, Xiao, Li, Chu, Huikuan, Du, Fan, Zhu, Qingjing, Schnabl, Bernd, Huang, Kai, Yang, Ling, Hou, Xiaohua · 2018 · British Journal of Pharmacology

Abstract

Background and Purpose: The gut–liver axis is associated with the progression of non‐alcoholic fatty liver disease (NAFLD). Targeting the gut–liver axis and bile acid‐based pharmaceuticals are potential therapies for NAFLD. The effect of tauroursodeoxycholic acid (TUDCA), a candidate drug for NAFLD, on intestinal barrier function, intestinal inflammation, gut lipid transport and microbiota composition was analysed in a murine model of NAFLD. Experimental Approach: The NAFLD mouse model was established by feeding mice a high‐fat diet (HFD) for 16 weeks. TUDCA was administered p.o. during the last 4 weeks. The expression levels of intestinal tight junction genes, lipid metabolic and inflammatory genes were determined by quantitative PCR. Tissue inflammation was evaluated by haematoxylin and eosin staining. The gut microbiota was analysed by 16S rRNA gene sequencing. Key Results: TUDCA administration attenuated HFD‐induced hepatic steatosis, inflammatory responses, obesity and insulin resistance in mice. Moreover, TUDCA attenuated gut inflammatory responses as manifested by decreased intestinal histopathology scores and inflammatory cytokine levels. In addition, TUDCA improved intestinal barrier function by increasing levels of tight junction molecules and the solid chemical barrier. The components involved in ileum lipid transport were also reduced by TUDCA administration in HFD‐fed mice. Finally, the TUDCA‐treated mice showed a different gut microbiota composition compared with that in HFD‐fed mice but similar to that in normal chow diet‐fed mice. Conclusions and Implications: TUDCA attenuates the progression of HFD‐induced NAFLD in mice by ameliorating gut inflammation, improving intestinal barrier function, decreasing intestinal fat transport and modulating intestinal microbiota composition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.14095

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 204

Metadata

Authors
Wang, W., Zhao, J., Gui, W., Sun, D., Dai, H., Xiao, L., Chu, H., Du, F., Zhu, Q., Schnabl, B., Huang, K., Yang, L., & Hou, X.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2018-01-03
Volume
175
Issue
3
Pages
469-484
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2797884982
Cited by
204
References
21
FWCI
3.71
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non‐alcoholic fatty liver disease. https://app.cochat.ai/papers/10.1111/bph.14095
The paper
Wang, W., Zhao, J., Gui, W., Sun, D., Dai, H., Xiao, L., Chu, H., Du, F., Zhu, Q., Schnabl, B., Huang, K., Yang, L., & Hou, X. (2018). Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non‐alcoholic fatty liver disease. British Journal of Pharmacology. https://doi.org/10.1111/bph.14095

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.